Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
NJ Holwerda, R Fogari, P Angeli… - Journal of …, 1996 - journals.lww.com
Objective: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
[引用][C] Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
NJ HOLWERDA, R FOGARI, P ANGELI… - Journal of …, 1996 - pascal-francis.inist.fr
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension :
efficacy and safety compared with placebo and enalapril CNRS Inist Pascal-Francis CNRS …
efficacy and safety compared with placebo and enalapril CNRS Inist Pascal-Francis CNRS …
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
N Holwerda, R Fogari, P Angeli, C Porcellati… - JOURNAL OF …, 1996 - iris.unipv.it
OBJECTIVE: To compare the antihypertensive efficacy and systemic tolerability of valsartan,
a new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
a new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
NJ Holwerda, R Fogari, P Angeli… - Journal of …, 1996 - pubmed.ncbi.nlm.nih.gov
Objective To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
NJ Holwerda, R Fogari, P Angeli, C Porcellati… - Journal of …, 1996 - europepmc.org
Objective To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …